MA-ULTIVUE
9.3.2022 11:02:08 CET | Business Wire | Press release
Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Aignostics GmbH, a global leader in Artificial Intelligence (AI) powered precision diagnostics focused on pathology to assist with research, clinical trials and CDx development, announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.
The companies have already been working together since early 2021 to adapt Aignostics’ client platform to support visualization and analysis for some of Ultivue’s products and services, as well as provisioning of results and corresponding reports. The resulting co-developed platform will now be made available to joint clients. Additionally, proof of concept work conducted on the Ultivue 12-plex Immunophenotyping biomarker panel in over 1,000 clinical NSCLC cases has demonstrated encouraging results for the capacity of AI-based analysis of multiplexed images for more consistent and reproducible readouts at scale. These results will be published later this year and respective AI models made available via the platform.
The companies are now expanding their relationship under a co-marketing agreement to offer the multiplex immunofluorescence (mIF) platform to their respective biotech and pharma clients, initially for research use, with a GCP-compliant version to follow later this year. Moreover, Ultivue and Aignostics will offer AI-powered image analysis services within the platform via Aignostics “Explainable AI” approach for the consistent and precise analysis of mIF cohorts at scale, for both translational research and clinical trial research services in Ultivue’s CLIA accredited clinical research laboratory. “We are excited to extend our workflow offering to include mIF AI for highly automated image analysis by partnering with Aignostics,” says Florian Leiss, VP Digital Health at Ultivue. “Improved viewing capabilities enable us to interactively explore the interplay of mIF-labeled cell populations in the histological context of same-slide H&E.”
“We believe that development of Ultivue’s assays with our AI-powered image analysis will create insights from data at scale that are unprecedented in spatial biology today. We are excited to start offering this approach to our clients for translational science and clinical trials,” said Viktor Matyas, CEO of Aignostics.
Besides offering research and development services to its clients, Ultivue and Aignostics will also develop products for standardized analysis of certain Ultivue products, paving the way for more widespread use of these technologies in both clinical trials and clinical routine.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
About Aignostics
Aignostics, a Berlin based company with offices in the US, is a digital pathology company dedicated to novel precision diagnostics through the use of a proprietary “Explainable AI” platform in pre-clinical and translational research and clinical trials. The use of such technology is expected to be crucial to implementation of AI-powered algorithms in routine diagnostics in order to verify (explain) the model’s decision outputs. Additionally, through its close alignment to Charité and TU Berlin amongst other collaborators, only Aignostics offers the combination of data access, sample testing and pathology expertise to develop digital pathology algorithms spanning multi-modal biomarker assay detection systems such as H&E, IHC and mIF, amongst others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aircall Acquires Piper AI to Turn Customer Conversations Into Revenue Action3.6.2026 12:03:00 CEST | Press release
The acquisition extends Aircall from AI-powered customer communications into multi-channel agentic revenue execution—automating follow-ups with prospects, CRM updates, deal scoring, and next steps after every customer interaction. Aircall, the AI-powered customer communications platform trusted by more than 23,000 businesses worldwide, today announced the acquisition of Piper AI, a revenue intelligence and agentic sales orchestration company. With Piper, Aircall extends its platform beyond the conversation itself—giving sales teams the tools to automatically act on every interaction, across every channel, from first touch to closed deal. Aircall already powers the conversations that drive revenue. Its platform unifies voice, SMS, and WhatsApp into a single workspace, with its AI Assist suite guiding sales reps before each call with account briefs, coaching them live with real-time playbooks and objection prompts, and automatically logging calls, generating summaries, and drafting follo
Rezon Bio Appoints Dr. Ralf Otto as Chief Operating Officer to Support Next Phase of Growth and Operational Expansion3.6.2026 12:01:00 CEST | Press release
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Ralf Otto, as Chief Operating Officer (COO) effective June 1, 2026. In his role, Ralf Otto, PhD, will be responsible for the operational areas of clinical and commercial cGMP manufacturing, development, quality, engineering and business operations across Rezon Bio’s integrated end-to-end CDMO platform. His appointment comes as Rezon Bio enters its next phase of growth, focused on broadening its service offering, expanding its global client base, and improving access to biosimilars and novel biologics through operational excellence, scalability, and enhanced price competitiveness. Ralf Otto, PhD, brings more than 25 years of international leadership experience across the CDMO and biopharmaceutical industry, with extensive expertise in biologics development, clinical and commercial cGMP manufacturing, technology transfer, manufacturing scale-up
Danube Properties Expands UK Presence with New London Office, Eyes Wider European Growth3.6.2026 11:34:00 CEST | Press release
Danube Properties, one of the UAE’s leading real estate developers, is set to strengthen its international presence with the launch of its new sales office in Central London. Located at 44 Brompton Road, Knightsbridge, SW3 1BW, the new office marks another milestone in the company’s growing expansion across the United Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260530149191/en/ Atif Farid, Head Business Development (UK); Rizwan Sajan, Founder and Chairman of Danube Group; and Adel Sajan, Managing Director of Danube Group, at the launch of Danube Properties' new sales office in Central London. (Photo: AETOSWire) The opening follows the successful launch of Danube Properties’ first UK office in Harrow two years ago, which established a strong connection with investors and homebuyers seeking premium Dubai real estate opportunities. Building on this momentum, the new Knightsbridge office aims to provide enhanced acce
Sensofusion Introduces its Aerospace Unit: Swift Surveillance Aircraft and Fennec Satellites3.6.2026 11:30:00 CEST | Press release
Finnish defence technology company Sensofusion Oy is expanding its operations from the ground to the air and into Earth orbit. As of today, the company's aviation and space business will operate under the name Sensofusion Aerospace.The unit's ongoing product development projects are the Sensofusion Swift surveillance aircraft and the company's first two satellite missions, Fennec-1 and Fennec-2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603447178/en/ With the Fennec-satellite program, Sensofusion's sensing capability extends into Earth orbit. Sensofusion Swift is a type-certified general aviation aircraft with integrated signals intelligence capability, radar and other advanced sensors. Unlike unmanned systems, Swift can operate in peacetime airspace near airports and population centres without separate exemptions. Sensofusion Swift is both an aircraft and a drone. It can be procured and operated either as a crewed g
Swedish Court Reschedules Publication of Judgment in PriceRunner Vs Google Antitrust Case3.6.2026 10:34:00 CEST | Press release
Klarna provides investor update Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from 10 June to 26 June, 2026 at 11:00 CET. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former PriceRunner shareholders and Klarna’s litigation funder, and to applicable taxation. The dollar amount of the claim should not be taken as an indication of any likely recovery. This announcement does not constitute a profit forecast. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom